Actemra (Tocilizumab) Market Report 2026

Actemra (Tocilizumab) Market Overview

• The Actemra (Tocilizumab) market growth in the historic period has been driven by established role of il 6 in inflammation, rising rheumatoid arthritis prevalence • Market expansion is supported by increasing autoimmune disease burden, expansion into new inflammatory indications • Growth Driver: Rising Prevalence Of Rheumatoid Arthritis Driving Growth In The actemra (tocilizumab) Market • Market Trend: Emergence Of Biosimilars For Autoimmune Diseases And COVID-19 Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Actemra (Tocilizumab) Market?

Actemra (Tocilizumab) is a prescription biologic medication classified as an interleukin-6 (IL-6) receptor antagonist, used to treat various autoimmune and inflammatory conditions. It works by inhibiting IL-6, a cytokine involved in inflammation, helping to reduce symptoms and prevent disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome. The main product types of actemra (tocilizumab) are min purity less than 98%, min purity 98%-99%, and min purity more than 99%. dosage. The min purity less than 98% includes tocilizumab products with a purity level below 98% and may contain more impurities or residual components, which could affect their overall efficacy and safety. The dosages are injection, solution, and concentrate, and routes of administration include oral, parenteral, and others. The distribution channels are hospital pharmacy, retail pharmacy, and online pharmacy, and it is used in various applications such as cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).

What Is The Actemra (Tocilizumab) Market Growth Forecast?

The actemra (tocilizumab) market size is expected to see rapid growth in the next few years. It will grow to $9.34 million in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing autoimmune disease burden, expansion into new inflammatory indications, growth of biologic infusion centers, improved early diagnosis rates, rising biologic therapy access. Major trends in the forecast period include expanded use in autoimmune and inflammatory disorders, growing adoption in cytokine release syndrome management, increased hospital based biologic administration, rising focus on early il 6 targeted intervention, enhanced long term safety monitoring of biologics.

Global Actemra (Tocilizumab) Market Segmentation

1) By Product Type: Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99% 2) By Dosage: Injection, Solution, Concentrate 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By Application: Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA)

What Is The Driver Of The Actemra (Tocilizumab) Market?

The rising prevalence of rheumatoid arthritis is expected to propel the growth of the actemra (tocilizumab) market going forward. Rheumatoid arthritis refers to the chronic autoimmune condition that leads to joint inflammation, damage, and reduced quality of life, affecting millions globally. Rheumatoid arthritis is influenced by factors such as smoking and obesity, environmental exposures, and hormonal factors. Actemra (tocilizumab) is used in rheumatoid arthritis to reduce inflammation and prevent joint damage by inhibiting the interleukin-6 (IL-6) receptor, particularly in patients not responding to other treatments. For instance, in April 2024, according to data published by the National Institute for Health and Care Research (NIHR), a UK-based government agency, approximately 700,000 people in the UK are living with rheumatoid arthritis. Additionally, in June 2024, according to a report published by the Australian Institute of Health and Welfare, Australia-based national agency, approximately 514,000 people (2.0% of the population) in Australia were living with rheumatoid arthritis in 2022. In 2023, the condition accounted for 2.0% of the total disease burden and 16% of the disease burden for musculoskeletal conditions. Additionally, rheumatoid arthritis was linked to 1,322 deaths in 2022, equating to 5.1 deaths per 100,000 people and representing 0.7% of all deaths. Therefore, the rising prevalence of rheumatoid arthritis drive the actemra (tocilizumab) industry.

Key Players In The Global Actemra (Tocilizumab) Market

Major companies operating in the actemra (tocilizumab) market are Roche Holding AG, Fresenius Kabi

Global Actemra (Tocilizumab) Market Trends and Insights

Major companies operating in the actemra (tocilizumab) market is focusing on developing advanced solutions, such as tocilizumab biosimilar to gain a competitive edge in the industry. Tocilizumab biosimilars are approved for treating autoimmune diseases and COVID-19, offering an alternative to the originator drug Actemra. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for the treatment of multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.

What Are Latest Mergers And Acquisitions In The Actemra (Tocilizumab) Market?

In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, collaborated with Biogen Inc. The partnerships aimed to publish Phase 3 Clinical Trial Data for TOFIDENCE (BAT1806/BIIB800), an approved biosimilar to Actemra/RoActemra (tocilizumab). Currently marketed as TOFIDENCE, the biosimilar aims to enhance treatment accessibility for autoimmune conditions. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases.

Regional Insights

North America was the largest region in the actemra (Tocilizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Actemra (Tocilizumab) Market?

The actemra (tocilizumab) market consists of sales of intravenous (IV) and subcutaneous (SC) formulations used to treat autoimmune and inflammatory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Actemra (Tocilizumab) Market Report 2026?

The actemra (tocilizumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the actemra (tocilizumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.